Last reviewed · How we verify
ALK HDM AIT 6 DU
ALK HDM AIT 6 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration.
ALK HDM AIT 6 DU is an allergen immunotherapy (AIT) vaccine that desensitizes the immune system to house dust mite (HDM) allergens through repeated subcutaneous administration. Used for House dust mite allergic rhinitis and/or asthma.
At a glance
| Generic name | ALK HDM AIT 6 DU |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Allergen immunotherapy vaccine |
| Target | House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This is an allergy immunotherapy product containing modified house dust mite allergen extracts designed to induce immune tolerance. By gradually exposing patients to increasing doses of HDM allergens, the treatment shifts the immune response from IgE-mediated hypersensitivity toward IgG-mediated tolerance and regulatory T cell activation, reducing allergic symptoms and airway hyperresponsiveness.
Approved indications
- House dust mite allergic rhinitis and/or asthma
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Rhinitis symptoms
- Asthma exacerbation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALK HDM AIT 6 DU CI brief — competitive landscape report
- ALK HDM AIT 6 DU updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI